Second dose of the BNT162b2 mRNA vaccine: Value of timely administration but questionable necessity among the seropositive.

导出 OA

翻译打印收藏纠错

第一作者： Konstantina,Kontopoulou

第一单位： Department of Microbiology, G. Gennimatas General Hospital, Thessaloniki, Greece.

作者： Konstantina,Kontopoulou ^[1] ; Alexandra,Ainatzoglou ^[2] ; Christos T,Nakas ^[3] ; Athina,Ifantidou ^[1] ; Georgia,Goudi ^[4] ; Eleni,Antoniadou ^[5] ; Vasilios,Adamopoulos ^[1] ; Nikitas,Papadopoulos ^[1] ; Georgios,Papazisis ^[6]

作者单位： Department of Microbiology, G. Gennimatas General Hospital, Thessaloniki, Greece. ^[1] Department of Clinical Pharmacology, School of Medicine, Aristotle University of Thessaloniki, Greece. ^[2] Laboratory of Biometry, University of Thessaly, Magnesia, Greece; University Institute of Clinical Chemistry, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. ^[3] Department of Cardiology, G. Gennimatas General Hospital, Thessaloniki, Greece. ^[4] Intensive Care Unit, G. Gennimatas General Hospital, Thessaloniki, Greece. ^[5] Department of Clinical Pharmacology, School of Medicine, Aristotle University of Thessaloniki, Greece; Clinical Trials Unit, Special Unit for Biomedical Research and Education, School of Medicine, Aristotle University of Thessaloniki, Greece. Electronic address: papazisg@auth.gr. ^[6]

关键词 BNT162b2 mRNA vaccine Greece Immunogenicity Seropositive

主题词抗体, 病毒(Antibodies, Viral);人类(Humans);中年人(Middle Aged);RNA, 信使(RNA, Messenger)

DOI 10.1016/j.vaccine.2021.07.065

PMID 34344551

发布时间 2024-09-08

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交